UroSens urosens.com

UroSens is developing diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. The Company has a worldwide exclusive license, from Cancer Research Technology, for the exploitation of MCM cancer biomarkers in the diagnosis of bladder and prostate cancer, using quantitative immunoassays. MCM proteins are excellent biomarkers, being directly involved in cell replication and are shed into urine by both prostate and bladder tumours. The ubiquitous nature of MCMs, ...Show all

UroSens is developing diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. The Company has a worldwide exclusive license, from Cancer Research Technology, for the exploitation of MCM cancer biomarkers in the d...Show all

Company (Alive / Active)

All investors data 5 Investors

• Beer & Partners
• Cambridge Capital Group
• Esperante
• Innovate UK
• Northstar Ventures

Competitors

Patents